Hengsai Bio key facts
- Developer of personalized dendritic cell tumor vaccines intended to provide new treatment approaches and strategies for relapsed and refractory tumors.
- It has raised $18.6M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Zhongshan Finance Investment, Fuho Capital, Zhongshan Xiwan Investment Holding Development, CuiHeng Group, Bison Capital Financial Holdings — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch Hengsai Bio: the Monday email on marks, rounds and moves
Hengsai Bio funding rounds
No funding rounds for Hengsai Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Hengsai Bio investors
7 investors are on record for Hengsai Bio, including Zhongshan Finance Investment, Fuho Capital, Zhongshan Xiwan Investment Holding Development and CuiHeng Group.
About Hengsai Bio
Developer of personalized dendritic cell tumor vaccines intended to provide new treatment approaches and strategies for relapsed and refractory tumors. The company's vaccines focuses on on the field of tumor immunotherapy and has been developed to treat relapsed and refractory tumors, chronic viral infections, autoimmune diseases and other diseases that are in urgent need of effective clinical treatments, enabling healthcare professionals to administer treatments and vaccines with safety, efficiency, and convenience in mind.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Hengsai Bio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.